Long-Term Data Confirm Durability Of Medtronic’s DTM Back Pain Therapy
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.
You may also be interested in...
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
Medtronic acquired Stimgenics, an Illinois company it previously helped to fund, for an undisclosed sum. The company plans to add Stimgenics’ differential target multiplexed spinal cord stimulation waveform to its Intellis spinal cord stimulation system for the treatment of chronic pain.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.